David I Bernstein1, Fernando J Bravo2, Derek A Pullum2, Hui Shen2, Mei Wang2, Aquilur Rahman3, Robert I Glazer4, Rhonda D Cardin2. 1. Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA David.Bernstein@cchmc.org. 2. Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA. 3. N & N Pharmaceuticals Inc., Rockville, MD, USA. 4. Georgetown University Medical Center, Washington, DC, USA.
Abstract
BACKGROUND: Current approved nucleoside therapies for genital herpes simplex virus (HSV) infections are effective but improved therapies are needed for treatment of both acute and recurrent diseases. METHODS: The effects of N-methanocarbathymidine were evaluated and compared to acyclovir using guinea pig models of acute and recurrent infection. For acute disease following intravaginal inoculation of 10(6 )pfu HSV-2 (MS strain), animals were treated intraperitoneally beginning 24 h post-infection, and the effects on disease severity, vaginal virus replication, subsequent recurrences, and latent virus loads were evaluated. For evaluation of recurrent infection, animals were treated for 21 days beginning 14 days after infection and disease recurrence and recurrent shedding were evaluated. RESULTS: Treatment of the acute disease with N-methanocarbathymidine significantly reduced the severity of acute disease and decreased acute vaginal virus shedding more effectively than acyclovir. Significantly, none of the animals developed visible disease in the high-dose N-methanocarbathymidine group and this was the only group in which the number of days with recurrent virus shedding was reduced. Treatment of recurrent disease was equivalent to acyclovir when acyclovir was continuously supplied in the drinking water. CONCLUSION: N-methanocarbathymidine was effective as therapy for acute and recurrent genital HSV-2 disease in the guinea pig models.
BACKGROUND: Current approved nucleoside therapies for genital herpes simplex virus (HSV) infections are effective but improved therapies are needed for treatment of both acute and recurrent diseases. METHODS: The effects of N-methanocarbathymidine were evaluated and compared to acyclovir using guinea pig models of acute and recurrent infection. For acute disease following intravaginal inoculation of 10(6 )pfu HSV-2 (MS strain), animals were treated intraperitoneally beginning 24 h post-infection, and the effects on disease severity, vaginal virus replication, subsequent recurrences, and latent virus loads were evaluated. For evaluation of recurrent infection, animals were treated for 21 days beginning 14 days after infection and disease recurrence and recurrent shedding were evaluated. RESULTS: Treatment of the acute disease with N-methanocarbathymidine significantly reduced the severity of acute disease and decreased acute vaginal virus shedding more effectively than acyclovir. Significantly, none of the animals developed visible disease in the high-dose N-methanocarbathymidine group and this was the only group in which the number of days with recurrent virus shedding was reduced. Treatment of recurrent disease was equivalent to acyclovir when acyclovir was continuously supplied in the drinking water. CONCLUSION: N-methanocarbathymidine was effective as therapy for acute and recurrent genital HSV-2 disease in the guinea pig models.
Authors: J M Douglas; C Critchlow; J Benedetti; G J Mertz; J D Connor; M A Hintz; A Fahnlander; M Remington; C Winter; L Corey Journal: N Engl J Med Date: 1984-06-14 Impact factor: 91.245
Authors: Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes Journal: N Engl J Med Date: 2004-01-01 Impact factor: 91.245
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: David I Bernstein; Fernando J Bravo; Jennifer R Clark; Julie D Earwood; Aquilur Rahman; Robert Glazer; Rhonda D Cardin Journal: Antiviral Res Date: 2011-09-07 Impact factor: 10.103
Authors: Pierre Schelling; Michael T Claus; Regula Johner; Victor E Marquez; Georg E Schulz; Leonardo Scapozza Journal: J Biol Chem Date: 2004-05-25 Impact factor: 5.486
Authors: David I Bernstein; Rhonda D Cardin; Derek A Pullum; Fernando J Bravo; Konstantin G Kousoulas; David A Dixon Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Sita Awasthi; Peiwen Lu; Derek A Pullum; David A Dixon; Akiko Iwasaki; Harvey M Friedman Journal: NPJ Vaccines Date: 2019-08-01 Impact factor: 7.344
Authors: David I Bernstein; Rhonda D Cardin; Gregory A Smith; Gary E Pickard; Patricia J Sollars; David A Dixon; Rajamouli Pasula; Fernando J Bravo Journal: NPJ Vaccines Date: 2020-11-06 Impact factor: 7.344